Enzo Biochem (ENZB) AI Stock Analysis

• Market Cap: $36.59M
• Dividend Yield: N/A
• Average Volume (3M): 61.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.93
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 125
• Sector: Healthcare
• Sector Strength: 52
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.05
• Shares Outstanding: 52,353,000
• 10 Day Avg. Volume: 67,050
• 30 Day Avg. Volume: 61,292
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.23
• Enterprise Value/Revenue: -0.31
• Enterprise Value/Gross Profit: -0.71
• Enterprise Value/Ebitda: 1.27
• 1Y Price Target: $0.50
• Price Target Upside: -28.57% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: $0.50 ▼(-28.57% Downside)

Enzo Biochem's overall stock score is primarily impacted by its challenging financial performance and valuation issues due to declining revenues and profitability. However, the upcoming merger with Battery Ventures provides a positive outlook, offering a significant premium and a strategic path forward. Technical analysis shows potential short-term gains but also warns of overbought conditions.

Enzo Biochem Business Overview & Revenue Model

Company Description

Enzo Biochem, Inc. is a biotechnology company based in the United States, focused on the development and commercialization of innovative diagnostic products and therapeutic solutions. The company operates in two primary segments: Clinical Laboratory Services and Bioservices. Enzo's core products include molecular diagnostic tests, genetic testing services, and research reagents, aimed at enhancing disease detection and patient care across various healthcare settings.

How the Company Makes Money

Enzo Biochem generates revenue through a diverse range of sources. The Clinical Laboratory Services segment contributes significantly to its earnings by offering a variety of diagnostic testing services, including molecular diagnostics and genetic testing, to healthcare providers and patients. This segment typically operates on a fee-for-service model, where revenue is earned by charging for each test performed. Additionally, the Bioservices segment, which includes the sale of research reagents and laboratory services, also plays a crucial role in revenue generation. Enzo has established partnerships with various healthcare institutions and research organizations, enabling it to expand its market reach and develop new products. Furthermore, the company may benefit from collaborations and licensing agreements that provide additional income streams while enhancing its portfolio of offerings.

Enzo Biochem Financial Statement Overview

Summary

Enzo Biochem's financial performance is under pressure due to declining revenues and losses, as indicated by the income statement. The balance sheet shows moderate stability with low leverage, but the cash flow analysis highlights significant challenges with negative free cash flow and operating cash flow. Overall, the company is facing substantial financial hurdles, risking long-term sustainability without a turnaround.

Income Statement

Enzo Biochem's income statement reveals a challenging financial position with declining revenues and persistent losses. The company experienced a significant revenue drop from previous years, coupled with negative net income and EBIT margins in TTM (Trailing-Twelve-Months). The gross profit margin stands at 43.75%, indicating some cost management effectiveness, but the negative net profit margin of -76.75% highlights profitability issues.

Balance Sheet

The balance sheet shows moderate stability with a debt-to-equity ratio of 0.07, reflecting low leverage. However, the declining stockholders' equity and total assets suggest a shrinking balance sheet. The equity ratio of 68.34% indicates that a significant portion of assets is financed by equity, which is a positive sign of financial health.

Cash Flow

Cash flow analysis indicates significant challenges, with a negative free cash flow and operating cash flow in TTM. The company showed a negative free cash flow growth rate, reflecting cash generation issues. The operating cash flow to net income ratio is unfavorable, indicating that operations are not generating enough cash to cover losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.48M	31.91M	31.06M	107.07M	117.73M	76.02M
Gross Profit	12.02M	14.63M	11.57M	41.97M	53.58M	23.77M
EBITDA	-6.72M	-8.35M	-20.94M	-15.01M	3.35M	-27.59M
Net Income	-21.08M	-26.08M	20.29M	-22.58M	3.42M	-33.89M
Balance Sheet
Total Assets	63.52M	85.76M	121.88M	95.86M	113.69M	112.54M
Cash, Cash Equivalents and Short-Term Investments	36.69M	52.37M	82.37M	21.60M	43.50M	47.87M
Total Debt	3.00M	3.51M	7.00M	20.59M	22.68M	32.79M
Total Liabilities	20.12M	29.65M	43.42M	41.40M	45.10M	54.16M
Stockholders Equity	43.40M	56.11M	78.46M	54.46M	68.59M	58.38M
Cash Flow
Free Cash Flow	-16.35M	-26.80M	-39.74M	-20.06M	-4.05M	-19.35M
Operating Cash Flow	-15.32M	-26.26M	-36.98M	-16.59M	387.00K	-17.18M
Investing Cash Flow	3.97M	-545.00K	98.98M	25.22M	-34.50M	-2.17M
Financing Cash Flow	-9.18M	-4.19M	-1.13M	-241.00K	-242.00K	7.00M

Enzo Biochem Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENZB, the sentiment is Positive. The current price of 0.7 is above the 20-day moving average (MA) of 0.69, above the 50-day MA of 0.67, and above the 200-day MA of 0.64, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 68.87 is Neutral, neither overbought nor oversold. The STOCH value of 106.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENZB.

Enzo Biochem Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	62 Neutral	$28.73M	―	-14.76%	―	27.05%	55.03%
ENZB	54 Neutral	$36.59M	―	-13.95%	―	―	―
Sector *	51 Neutral	$7.95B	-0.38	-43.43%	2.22%	22.30%	-1.83%
INBS	50 Neutral	$13.92M	―	-186.64%	―	-1.90%	87.72%
BDSX	47 Neutral	$64.72M	―	-219.68%	―	25.70%	39.23%
BIAF	44 Neutral	$6.80M	―	-1802.45%	―	4.99%	22.58%
VNRX	43 Neutral	$64.77M	―	138.92%	―	35.10%	39.15%

Enzo Biochem Corporate Events

Enzo Biochem Completes Merger, Delists from OTCQX

Enzo Biochem has completed a merger that resulted in significant changes to its corporate structure and stock status. As of August 20, 2025, the company’s common stock ceased trading on the OTCQX market, and the company plans to deregister its stock with the SEC. The merger led to the cancellation of outstanding shares, restricted stock units, options, and warrants, with certain stakeholders receiving cash considerations. Additionally, several directors stepped down, and the company’s certificate of incorporation and bylaws were amended in accordance with the merger agreement.

Enzo Biochem Shareholders Approve Merger with Bethpage

On August 19, 2025, Enzo Biochem, Inc. held a special meeting of shareholders where they approved a merger agreement with Bethpage Parent, Inc. and its subsidiary. This merger involves Bethpage Merger Sub, Inc. merging with and into Enzo Biochem. The approval of the merger proposal negated the need for an adjournment proposal, and the merger is expected to close around August 20, 2025.

Enzo Biochem Announces Merger with Battery Ventures

On June 23, 2025, Enzo Biochem, Inc. entered into a merger agreement to be acquired by Battery Ventures for $0.70 per share in cash, totaling approximately $37 million. This transaction, which follows a strategic review by Enzo’s Board, represents a 75% premium to the company’s closing price on April 22, 2025. The merger is subject to customary closing conditions, including shareholder approval, and is expected to close in the third quarter of 2025. Upon completion, Enzo will become a privately held company, and its shares will no longer be publicly traded. The acquisition is seen as a strategic move to maximize shareholder value.